Agonistas beta2 y antagonistas muscarínicos de acción prolongada / 24 horas en inhalador combinado vs placebo para la enfermedad pulmonar obstructiva crónica (EPOC): obtienen mejoría significativa en función pulmonar y calidad de vida EPOC leve a moderada.
8,929 followers
4 followers
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease - Maqsood, U - 2019 | Cochrane Library https://t.co/qL3kunLdhf
4 followers
RT @CochraneAirways: New #CochraneEvidence: Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inha…
2,485 followers
RT @ATS_BSHSR: Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for #COPD…